Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 9/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17110470 | 0.85 | PIN1 (0.47) | PIN1KMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL17110503 | 0.80 | PIN1 (0.43) | PIN1KMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL11903190 | 0.77 | KMT2A (0.48) | PIN1KMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL27538176 | 0.77 | ADORA1 (0.50) | PIN1KMT2AMEN1ALDH1A1 | |
| SCHEMBL12963787 | 0.73 | GPR84 (0.41) | KMT2AMEN1ALDH1A1TDP1TP53 | |
| SCHEMBL8257761 | 0.73 | PIN1 (0.39) | PIN1KMT2AMEN1ALDH1A1PIM3 | |
| SCHEMBL18231594 | 0.73 | PIN1 (0.60) | PIN1ALDH1A1 | |
| SCHEMBL18779303 | 0.73 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL25560081 | 0.71 | KMT2A (0.47) | KMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL6617821 | 0.70 | ALDH1A1 (0.53) | KMT2AMEN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815846-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NGF, NTRK1 | PIN1 1271/4885KMT2A 3308/4885MEN1 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.